Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Hill

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Pageof 8